Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) EBITDA (2020 - 2025)

Historic EBITDA for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to -$27.5 million.

  • Caribou Biosciences' EBITDA rose 1811.12% to -$27.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$157.8 million, marking a year-over-year decrease of 783.94%. This contributed to the annual value of -$148.9 million for FY2024, which is 4810.69% down from last year.
  • As of Q3 2025, Caribou Biosciences' EBITDA stood at -$27.5 million, which was up 1811.12% from -$54.2 million recorded in Q2 2025.
  • Caribou Biosciences' 5-year EBITDA high stood at -$9.8 million for Q3 2023, and its period low was -$54.2 million during Q2 2025.
  • For the 5-year period, Caribou Biosciences' EBITDA averaged around -$28.4 million, with its median value being -$27.3 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 53463.41% in 2021, then soared by 6366.55% in 2023.
  • Over the past 5 years, Caribou Biosciences' EBITDA (Quarter) stood at -$18.6 million in 2021, then tumbled by 42.22% to -$26.5 million in 2022, then dropped by 26.53% to -$33.5 million in 2023, then decreased by 7.55% to -$36.0 million in 2024, then grew by 23.68% to -$27.5 million in 2025.
  • Its EBITDA was -$27.5 million in Q3 2025, compared to -$54.2 million in Q2 2025 and -$40.1 million in Q1 2025.